|
1
|
Maheshwari V and Moser AJ: Current
management of locally advanced pancreatic cancer. Nat Clin Pract
Gastroenterol Hepatol. 2:356–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hines OJ and Reber HA: Pancreatic surgery.
Curr Opin Gastroenterol. 22:520–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan EW, Cheng SC, Sin FW and Xie Y:
Triptolide induced cytotoxic effects on human promyelocytic
leukemia, T cell lymphoma and human hepatocellular carcinoma cell
lines. Toxicol Lett. 122:81–87. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen C, Edelstein LC and Gelinas C: The
Rel/NF-kappaB family directly activates expression of the apoptosis
inhibitor Bcl-x(L). Mol Cell Biol. 20:2687–2695. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levy GN: Prostaglandin H synthases,
nonsteroidal anti-inflammatory drugs and colon cancer. FASEB J.
11:234–247. 1997.PubMed/NCBI
|
|
6
|
Sheng H, Shao J, Kirkland SC, Isakson P,
Coffey RJ, Morrow J, Beauchamp RD and DuBois RN: Inhibition of
human colon cancer cell growth by selective inhibition of
cyclooxygenase-2. J Clin Invest. 99:2254–2259. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Avis I, Hong SH, Martinez A, Moody T, Choi
YH, Trepel J, Das R, Jett M and Mulshine JL: Five-lipoxygenase
inhibitors can mediate apoptosis in human breast cancer cell lines
through complex eicosanoid interactions. FASEB J. 15:2007–2009.
2001.PubMed/NCBI
|
|
8
|
Ghosh J and Myers CE: Inhibition of
arachidonate 5-lipoxygenase triggers massive apoptosis in human
prostate cancer cells. Proc Natl Acad Sci USA. 95:13182–13187.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Werz O and Steinhilber D: Therapeutic
options for 5-lipoxygenase inhibitors. Pharmacol Ther. 112:701–718.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou GX, Ding XL, Huang JF, Zhang H and Wu
SB: Suppression of 5-lipoxygenase gene is involved in
triptolide-induced apoptosis in pancreatic tumor cell lines.
Biochim Biophys Acta. 1770:1021–1027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding XZ, Iversen P, Cluck MW, Knezetic JA
and Adrian TE: Lipoxygenase inhibitors abolish proliferation of
human pancreatic cancer cells. Biochem Biophys Res Commun.
261:218–223. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding XZ, Kuszynski CA, El-Metwally TH and
Adrian TE: Lipoxygenase inhibition induced apoptosis, morphological
changes and carbonic anhydrase expression in human pancreatic
cancer cells. Biochem Biophys Res Commun. 266:392–399. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ding XZ, Tong WG and Adrian TE:
12-Lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic
cancer cell proliferation via protein tyrosine phosphorylation and
ERK activation. Int J Cancer. 94:630–636. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang
F, Abraham S, Nayeemuddin K, Hunt K and Wu Y: Invasive
neuroendocrine carcinoma of the breast: A distinctive subtype of
aggressive mammary carcinoma. Cancer. 116:4463–4473. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marnett LJ and Honn KV: Overview of
articles on eicosanoids and cancer. Cancer Metastasis Rev.
13:237–239. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marnett LJ: Generation of mutagens during
arachidonic acid metabolism. Cancer Metastasis Rev. 13:303–308.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shureiqi I and Lippman SM: Lipoxygenase
modulation to reverse carcinogenesis. Cancer Res. 61:6307–6312.
2001.PubMed/NCBI
|
|
18
|
Chen X, Wang S, Wu N and Yang CS:
Leukotriene A4 hydrolase as a target for cancer prevention and
therapy. Curr Cancer Drug Targets. 4:267–283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tong WG, Ding XZ, Witt RC and Adrian TE:
Lipoxygenase inhibitors attenuate growth of human pancreatic cancer
xenografts and induce apoptosis through the mitochondrial pathway.
Mol Cancer Ther. 1:929–935. 2002.PubMed/NCBI
|
|
20
|
Chen X, Li N, Wang S, Wu N, Hong J, Jiao
X, Krasna MJ, Beer DG and Yang CS: Leukotriene A4 hydrolase in rat
and human esophageal adenocarcinomas and inhibitory effects of
bestatin. J Natl Cancer Inst. 95:1053–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoque A, Lippman SM, Wu TT, Xu Y, Liang
ZD, Swisher S, Zhang H, Cao L, Ajani JA and Xu XC: Increased
5-lipoxygenase expression and induction of apoptosis by its
inhibitors in esophageal cancer: a potential target for prevention.
Carcinogenesis. 26:785–791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hennig R, Ding XZ, Tong WG, Schneider MB,
Standop J, Friess H, Büchler MW, Pour PM and Adrian TE:
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human
pancreatic cancers but not in pancreatic ducts in normal tissue. Am
J Pathol. 161:421–428. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Avis I, Hong SH, Martinez A, Moody T, Choi
YH, Trepel J, Das R, Jett M and Mulshine JL: Five-lipoxygenase
inhibitors can mediateapoptosis in human breast cancer cell lines
through complex eicosanoid interactions. FASEB J. 15:2007–2009.
2001.PubMed/NCBI
|
|
24
|
Gupta S, Srivastava M, Ahmad N, Sakamoto
K, Bostwick DG and Mukhtar H: Lipoxygenase-5 is overexpressed in
prostate adenocarcionma. Cancer. 91:737–743. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anderson KM, Seed T, Vos M, Mulshine J,
Meng J, Alrefai W, Ou D and Harris JE: 5-Lipoxygenase inhibitors
reduce PC-3 cell proliferation and initiate nonnecrotic cell death.
Prostate. 37:161–173. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ye YN, Liu ES, Shin VY, Wu WK and Cho CH:
Contributory role of 5-lipoxygenase and its association with
angiogenesis in the promotion of inflammation-associated colonic
tumorigenesis by cigarette smoking. Toxicology. 203:179–188. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeng ZZ, Yellaturu CR, Neeli I and Rao GN:
5(S)-hydroxy eicosatetraenoic acid stimulates DNA synthesis in
human microvascular endothelial cells via activation of Jak/STAT
and phosphatidylinositol 3-kinase/Akt signaling, leading to
induction of expression of basic fibroblast growth factor. J Biol
Chem. 277:41213–41219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wenger FA, Kilian M, Bisevac M, Khodadayan
C, von Seebach M, Schimke I, Guski H and Muller JM: Effects of
Celebrex and Zyflo on liver metastasis and lipidperoxidation in
pancreatic cancer in Syrian hamster. Clin Exp Metastasis.
19:681–687. 2002. View Article : Google Scholar
|
|
29
|
Gabbert HE, Meier S, Gerharz CD and Hommel
G: Incidence and progostic significance of vascular invasion in 529
gastric-cancer patients. Int J Cancer. 49:203–207. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wenger FA, Kilian M, Achucarro P, et al:
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in
Syrian hamsters. Pancreatology. 2:54–60. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li N, Sood S, Wang S, Fang M, Wang P, Sun
Z, Yang CS and Chen X: Overexpression of 5-lipoxygenase and
cyclooxygenase 2 in hamster and human oral cancer and
chemopreventive effects of zileuton and celecoxib. Clin Cancer Res.
11:2089–2096. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Puignero V and Queralt J: Effect of
topically applied cyclooxygenase-2-selective inhibitors on
arachidonic acid- and tetradecanoylphorbol acetate-induced dermal
inflammation in the mouse. Inflammation. 21:431–442. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rao TS, Yu SS, Djuric SW and Isakson PC:
Phorbol ester-induced dermal inflammation in mice: evaluation of
inhibitors of 5-lipoxygenase and antagonists of leukotriene B4
receptor. J Lipid Mediat Cell Signal. 10:213–228. 1994.PubMed/NCBI
|
|
34
|
Gunning WT, Kramer PM, Steele VE and
Pereira MA: Chemoprevention by lipoxygenase and leukotriene pathway
inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer
Res. 62:4199–4201. 2002.PubMed/NCBI
|
|
35
|
Jiang H, Yamamoto S and Kato R: Inhibition
of two-stage skin carcinogenesis as well as complete skin
carcinogenesis by oral administration of TMK688, a potent
lipoxygenase inhibitor. Carcinogenesis. 15:807–812. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Wang S, Wu N, et al:
Overexpression of 5-lipoxygenase in rat and human esophageal
adenocarcinoma and inhibitory effects of zileuton and celecoxib on
carcinogenesis. Clin Cancer Res. 10:6703–6709. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Batt D: 5-Lipoxygenase inhibitors and
their anti-inflammatory activities. Prog Med Chem. 29:1–63. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Poff CD and Balazy M: Drugs that target
lipoxygenases and leukotrienes as emerging therapies for asthma and
cancer. Curr Drug Targets Inflamm Allergy. 3:19–33. 2004.
View Article : Google Scholar : PubMed/NCBI
|
